First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

被引：0
|
作者：
Ang, J. E. [1 ]
Hauns, B. [2 ]
Mais, A. [2 ]
Parker, A. [1 ]
Lal, R. [1 ]
Olmos, D. [1 ]
Mollenhauer, M. [2 ]
Walz, A. [2 ]
de Bono, J. S. [1 ]
机构：
[1] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[2] Nycomed GmbH, Exploratory Clin Dev, Constance, Germany
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72327-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / 124
页数：2
相关论文
共 50 条
  • [31] A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
    Trivedi, Neel D.
    Armstrong, Samantha
    Wang, Hongkun
    Hartley, Marion
    Deeken, John
    He, A. Ruth
    Subramaniam, Deepa
    Melville, Heather
    Albanese, Chris
    Marshall, John L.
    Hwang, Jimmy
    Pishvaian, Michael J.
    CANCER MEDICINE, 2021, 10 (06): : 1944 - 1954
  • [32] A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
    Gaillard, Stephanie L.
    Zahurak, Marianna
    Sharma, Anup
    Durham, Jennifer N.
    Reiss, Kim A.
    Sartorius-Mergenthaler, Susan
    Downs, Melinda
    Anders, Nicole M.
    Ahuja, Nita
    Rudek, Michelle A.
    Azad, Nilofer
    CANCER, 2019, 125 (16) : 2837 - 2845
  • [33] Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    O'Connor, OA
    Heaney, ML
    Schwartz, L
    Richardson, S
    Willim, R
    MacGregor-Cortelli, B
    Curly, T
    Moskowitz, C
    Portlock, C
    Horwitz, S
    Zelenetz, AD
    Frankel, S
    Richon, V
    Marks, P
    Kelly, WK
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 166 - 173
  • [34] A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
    Katharine A. Collier
    Hugo Valencia
    Herbert Newton
    Erinn M. Hade
    Douglas W. Sborov
    Robert Cavaliere
    Ming Poi
    Mitch A. Phelps
    Sophia G. Liva
    Christopher C. Coss
    Jiang Wang
    Soun Khountham
    Paul Monk
    Charles L. Shapiro
    Richard Piekarz
    Craig C. Hofmeister
    D. Bradley Welling
    Amir Mortazavi
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 599 - 611
  • [35] A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
    Collier, Katharine A.
    Valencia, Hugo
    Newton, Herbert
    Hade, Erinn M.
    Sborov, Douglas W.
    Cavaliere, Robert
    Poi, Ming
    Phelps, Mitch A.
    Liva, Sophia G.
    Coss, Christopher C.
    Wang, Jiang
    Khountham, Soun
    Monk, Paul
    Shapiro, Charles L.
    Piekarz, Richard
    Hofmeister, Craig C.
    Welling, D. Bradley
    Mortazavi, Amir
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 599 - 611
  • [36] Phase I trial of oral etoposide in combination with celecoxib in patients with advanced malignancies.
    Luu, TH
    Twardowski, P
    Leong, L
    Lim, D
    Morgan, R
    McNamara, M
    Portnow, J
    Ruel, C
    Shibata, S
    Synold, T
    Doroshow, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 241S - 241S
  • [37] Phase I trial of oral cyclophosphamide in combination with celecoxib in patients with advanced malignancies.
    Twardowski, P
    Chow, W
    Koczywas, M
    Leong, L
    Lim, D
    Margolin, K
    Morgan, R
    Ruel, C
    Shibata, S
    Synold, T
    Doroshow, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 240S - 240S
  • [38] Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
    Kummar, Shivaani
    Gutierrez, Martin
    Gardner, Erin R.
    Donovan, Erin
    Hwang, Kyunghwa
    Chung, Eun Joo
    Lee, Min-Jung
    Maynard, Kim
    Kalnitskiy, Mikhail
    Chen, Alice
    Melillo, Giovanni
    Ryan, Qin C.
    Conley, Barbara
    Figg, William D.
    Trepel, Jane B.
    Zwiebel, James
    Doroshow, James H.
    Murgo, Anthony J.
    CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5411 - 5417
  • [39] Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
    Aftimos, Philippe Georges
    Bechter, Oliver
    Awada, Ahmad
    Jungels, Christiane
    Dumez, Herlinde
    Huyvaert, Nathalie
    Costermans, Jo
    Lee, Chooi
    Meeus, Marie-Anne
    Burkard, Ute
    Musa, Hanny
    Zhao, Yihua
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies
    Rowinsky, EK
    de Bono, J
    Deangelo, DJ
    van Oosterom, A
    Morganroth, J
    Laird, GH
    Dugan, M
    Scott, JW
    Ottmann, OG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 224S - 224S
12345